Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies

被引：0

作者：

Schreiber, Stefan ^{[1
]}

Ferrante, Marc ^{[2
]}

Panaccione, Remo ^{[3
]}

Colombel, Jean-Frederic ^{[4
]}

Hisamatsu, Tadakazu ^{[5
]}

Lim, Allen ^{[6
]}

Lindsay, James ^{[7
]}

Rubin, David T.

Sandborn, William ^{[8
]}

Neimark, Ezequiel ^{[9
]}

Song, Alexandra ^{[9
]}

Liao, Xiaomei ^{[9
]}

Feng, Tian ^{[9
]}

Berg, Sofie ^{[9
]}

Wallace, Kori ^{[9
]}

D'Haens, Geert ^{[10
]}

机构：

[1] Univ Kiel, Univ Hosp Schleswig Holstein, Kiel, Schleswig Holst, Germany

[2] Univ Hosp Leuven, Leuven, Luxembourg, Belgium

[3] Univ Calgary, Cumming Sch Med, Inflammatory Bowel Dis Clin, Gastrointestinal Res, Calgary, AB, Canada

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Kyorin Univ, Sch Med, Tokyo, Japan

[6] John Flynn Private Hosp, Tugun, Qld, Australia

[7] Queen Mary Univ London, London, England

[8] Univ Calif San Diego, La Jolla, CA 92093 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Amsterdam Univ Med Ctr, Amsterdam, Noord Holland, Netherlands

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S695

引用

页码：S314 / S315

页数：2

共 50 条

[41] The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease
Kierkus, Jaroslaw
Dadalski, Maciej
Szymanska, Edyta
Oracz, Grzegorz
Wegner, Agnieszka
Gorczewska, Monika
Szymanska, Sylwia
Woynarowski, Marek
Ryzko, Jozef
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (05) : 495 - 500
[42] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
Reich, K.
Gooderham, M.
Thaci, D.
Crowley, J. J.
Ryan, C.
Kruger, J. G.
Tsai, T.
Flack, M.
Gu, Y.
Williams, D. A.
Thompson, E. H.
Paul, C.
[J]. EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
[43] Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND
Colombel, Jean-Frederic
Rutgeerts, Paul J.
Sandborn, William J.
Camez, Anne A.
Pollack, Paul F.
Chen, Naijun
Yang, Mei
Mulani, Parvez
Chao, Jingdong
[J]. GASTROENTEROLOGY, 2010, 138 (05) : S518 - S518
[44] Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Vermeire, Severine
Schreiber, Stefan
Petryka, Robert
Kuehbacher, Tanja
Hebuterne, Xavier
Roblin, Xavier
Klopocka, Maria
Goldis, Adrian
Wisniewska-Jarosinska, Maria
Baranovsky, Andrey
Sike, Robert
Stoyanova, Kremena
Tasset, Chantal
Van der Aa, Annegret
Harrison, Pille
[J]. LANCET, 2017, 389 (10066): : 266 - 275
[45] USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE AND REMISSION IN REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE: A MULTICENTRE COHORT STUDY
Ma, Christopher
Fedorak, Richard N.
Kaplan, Gilaad
Dieleman, Levinus A.
Devlin, Shane M.
Stern, Nathan
Kroeker, Karen I.
Seow, Cynthia H.
Leung, Yvette
Novak, Kerri L.
Halloran, Brendan P.
Huang, Vivian
Wong, Karen
Ghosh, Subrata
Panaccione, Remo
[J]. GASTROENTEROLOGY, 2017, 152 (05) : S410 - S411
[46] Annual Phase III Data on Risankizumab in Crohn's Disease Female Patients achieve endoscopic Response and clinical Remission even in the Maintenance Phase
不详
[J]. VISCERAL MEDICINE, 2021, 37 (04) : 325 - 325
[47] ENDOSCOPIC AND CLINICAL OUTCOMES OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE BY BASELINE DISEASE SEVERITY
Siegmund, Britta
Patel, Kamal V.
Torres, Esther A.
Lakatos, Peter L.
Seidelin, Jakob B.
Fleisher, Mark
Ford, Sharanya
Remple, Valencia
Lacerda, Ana P.
Anyanwu, Samuel
Garrison, Andrew
Panes, Julian
[J]. GASTROENTEROLOGY, 2023, 164 (06) : S1103 - S1103
[48] Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: Results of the CHARM Trial
Colombel, J.
Sandborn, W. J.
Rutgeerts, P.
Enns, R.
Hanauer, S. B.
Remo, P.
Schreiber, S.
Lomax, K. G.
Pollack, P. F.
[J]. GASTROENTEROLOGY, 2006, 131 (03) : 950 - 950
[49] Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
Li, K.
Hayden, K.
Wadman, E.
Bhagat, S.
Emrich, S.
Friedman, J. R.
Gasink, C.
Brodmerkel, C.
[J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S26 - S27
[50] Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials
Ferrante, M.
Cao, Q.
Fujii, T.
Rausch, A.
Neimark, E.
Song, A.
Wallace, K.
Kligys, K.
Zhou, Q.
Kalabic, J.
Feagan, B. G.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I027 - I028

← 1 2 3 4 5 →